Full-Time
Professional networking, residency tools, telehealth
$77k - $134k/yr
Remote in USA + 1 more
More locations: San Francisco, CA, USA
Remote
Remote within the United States; SF office optional.
See people who can refer or advise you
Doximity is a digital platform for United States healthcare professionals, offering a professional social network, a residency navigator, and telehealth services. Users join to connect with peers, share medical insights, track residency applications, and conduct remote patient visits. Revenue comes from targeted advertising to medical professionals, premium subscriptions, and telehealth usage fees. Its goal is to improve communication and collaboration among clinicians, support career development and residency placement, and expand access to care through convenient telehealth.
Company Size
501-1,000
Company Stage
IPO
Headquarters
San Francisco, California
Founded
2010
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
401(k) Retirement Plan
401(k) Company Match
Family Planning Benefits
Paid Vacation
Paid Holidays
Wellness Program
Timothy Cabral, a director at Doximity, sold 7,500 shares of Class A Common Stock on 7 August through a pre-arranged Rule 10b5-1 trading plan adopted in February. The sale occurred the day after Doximity's stock jumped 33% following earnings, though the timing was automatic rather than discretionary. The transaction reduced Cabral's direct holdings to 3,221 shares, but he retains 326,000 derivative securities. Doximity reported revenue of $156.6 million for the quarter, up 7%, whilst free cash flow fell 34% to $39.6 million. The company attributed the decline to accounts receivable timing. Doximity operates a cloud-based platform for healthcare practitioners and generates revenue through subscriptions from pharmaceutical companies and healthcare organisations. The stock had declined 50% over the prior year before the recent surge.
Doximity's Chief Accounting Officer Siddharth Sitaram disposed of 5,652 shares for $140,400 on 13 and 15 August, according to an SEC Form 4 filing. The transaction was non-discretionary and tax-related. It consisted of 3,882 shares withheld by the issuer to cover restricted stock unit vesting and 1,770 shares sold under a Rule 10b5-1 plan to satisfy tax obligations from an option exercise. Following the transaction, Sitaram maintains direct ownership of 93,122 shares and holds 59,000 derivative securities, with a post-transaction value of $2.31 million. Doximity operates a cloud-hosted digital platform for healthcare practitioners. The company reported trailing 12-month revenue of $655.6 million and net income of $167.0 million, with a market capitalisation of $4.6 billion.
Dutch Bros, the US coffee chain, is attracting attention for its strong same-store sales performance and expansion strategy. The company has achieved average same-store sales growth of 6% over the past two years and expects revenue growth of 27.7% for the next year. Meanwhile, two cash-generating companies face challenges. Doximity, the physician networking platform, has seen costs rise faster than revenue, with operating margins declining by 10.5 percentage points. Its estimated sales growth of 4.6% for the next 12 months suggests slowing demand. Silgan Holdings, the packaging supplier, has experienced annual revenue growth of just 4.7% over five years and earnings per share growth of only 2.4% annually.
Doximity reported Q2 revenue of $156.6 million, up 7.3% year on year and beating analyst estimates of $151.3 million. The medical professional network's adjusted earnings per share of $0.29 missed expectations by 4.2%. The company attributed growth to increased adoption of AI-powered clinical tools. CEO Jeffrey Tangney noted quarterly active workflow prescribers grew more than 30% year on year, with nearly half using AI tools. Operating margin declined to 21.5% from 37.4% in the prior year period. The company raised full-year revenue guidance to $676 million from $670 million but set EBITDA guidance below analyst estimates at $319 million. CFO Matthew Sonefeldt said higher AI usage prompted increased investment to capture long-term opportunities, explaining near-term margin pressure.
Wells Fargo downgraded Doximity to Underweight from Equal Weight with an $18 price target, days after the medical professionals' digital platform surged 32.58% on earnings. Analyst Stan Berenshteyn noted that whilst Doximity's outlook remains unchanged, the stock now trades near faster-growing peers at approximately 32 times earnings despite roughly 11% revenue growth over the past year. The analyst argued remaining upside depends on an AI narrative that is difficult to quantify in estimates. Survey work suggests wallet-share gains with top accounts are largely complete. The $18 target sits at the bottom of analyst estimates ranging to $47. Wells Fargo cited unfavourable risk-reward until Doximity's AI strategy produces clearer growth acceleration.